TG Therapeutics | TGTX - Selling And Administration Expenses


TG Therapeutics reported $50.73M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alaunos Therapeutics USD 585K 84K Sep/2025
Amgen USD 1.94B 237M Dec/2025
Ardelyx USD 75.92M 7.69M Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Bayer EUR 4.05B 647M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
Corcept Therapeutics USD 114.74M 7.77M Dec/2025
Curis USD 1.34M 3.45M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
J&J USD 6.75B 831M Dec/2025
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Novavax USD 25.53M 1.34M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025
Verastem USD 24.44M 12.17M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025